Biotechnology company
Issues related to FDA & HHS program funding; FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills; Issues related to H.R. 6, the 21st Century CURES Act; 
Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program; 
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement;
Issues relating to Prescription Drug User Fee Act and ASP +6; 
Issues related to comparative effectiveness and follow-on biologics;
Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); 
Issues concerning implementation of Patient Protection and Affordable Care Act; 
Drug pricing under 340B program;
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act; 
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; 
HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; 
Public Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs. Issues related to tax reform and tax extenders; 
Issues relating to corporate tax reform including the R&D tax credit and taxation of foreign-owned corporations Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); 
Issues concerning implementation of Patient Protection and Affordable Care Act; 
Drug pricing under 340B program; Reform of 340B program;
Cancer Patient Protection; 
Ongoing issues related to the implementation of the Affordable Care Act;
Comparative effectiveness research, and FDA approval of follow-on biologics;  Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit;
BUD - Budget/Appropriations MMM - Medicare/Medicaid TAX - Taxation/Internal Revenue Code CPT - Copyright/Patent/Trademark HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
RIVENDELL GROUP LLP
1440 G Street, NW, Washington, DC, 20005, US
MATTHEW BERZOK (LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch) NICK KOLOVOS (LA and Counsel, Rep. Anna Eshoo) MATTHEW BERZOK (LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch) NICK KOLOVOS (LA and Counsel, Rep. Anna Eshoo) MATTHEW BERZOK (LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch) NICK KOLOVOS (LA and Counsel, Rep. Anna Eshoo) MATTHEW BERZOK (LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch) NICK KOLOVOS (LA and Counsel, Rep. Anna Eshoo) MATTHEW BERZOK (LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch) NICK KOLOVOS (LA and Counsel, Rep. Anna Eshoo)
LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch LA and Counsel, Rep. Anna Eshoo LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch LA and Counsel, Rep. Anna Eshoo LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch LA and Counsel, Rep. Anna Eshoo LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch LA and Counsel, Rep. Anna Eshoo LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch LA and Counsel, Rep. Anna Eshoo